They won’t have much choice going forward.
The Senate on August 3 overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for childhood cancers.
The bill, part of a larger measure reauthorizing user fees imposed by the Food and Drug Administration (FDA), heads to President Donald J. Trump for his expected signature.
But when it comes to cancer, advocates say the FDA has too much latitude to exempt the industry from studying and developing help for kids.
Federal regulators often have not required companies that invest heavily in the four major cancers — breast, prostate, lung and colon — to research how the treatments they develop for those adult-oriented diseases might assist in addressing childhood cancers.
Over the past 20 years, the FDA has approved about 190 new cancer treatments for adults but only three for children, said Sen. Michael Bennet, a Colorado Democrat who co-sponsored the provision with Florida Republican Sen. Marco Rubio.
For King’s full story, click here.